Emcure Pharma Gains on JM Buy Call

  Published 8 months ago

Emcure Pharma rose 3.5% after JM Financial initiated coverage with a "buy" rating and strong growth outlook.

  • JM sees 27.5% upside with FY25–28 PAT CAGR forecast at 29%, led by domestic and export market growth.
  • New launches in women’s health, skincare, and the Sanofi tie-up are expected to support revenue momentum.
  • Export growth to be driven by complex generics, biosimilars, and ARV demand in global markets.

You might like these

OpenAI Teams Up with Google Cloud for AI Expansion

Lupin Q1 Profit Jumps 43%, Margins Up

Kolte-Patil Stock Gains on Blackstone Stake Approval

Baazar Style Turns Profitable in Q1

June 2025 ESI Payroll Growth Highlights

Hyundai Motor India Stock Surges, Hits All Time High

India Sees Foreign Investment Revival

News that matters the most ⚡